drugset
drugset / Trial / NCT05895825

A Study of EOC237 in Patients With Advanced Solid Tumor

NCT05895825 ↗

Phase 1 Recruiting 48 enrolled Shanghai Yiteng Jingang Bio-pharmaceutical Technology Co., Ltd
Non-randomizedSequentialOpen-labelTreatment

Summary

This research study is studying an investigational drug called EOC237 in Patients With Advanced Solid Tumor.

Timeline

Start
2023-07-26
Primary completion
2026-04-30
Completion
2026-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject EOC237 Unknown — Oral

Indications

neoplasm